DR. MICHAEL L MOHLER, PHARM.D.
Pharmacy at Macon Rd, Memphis, TN
License number
Tennessee 12163
Category
Pharmacy
Type
Pharmacist
Address
Address
6770 Macon Rd, Memphis, TN 38134
Phone
(901) 371-0255
Personal information
See more information about MICHAEL L MOHLER at radaris.comName
Address
Phone
6806 Century Oaks Dr, Cordova, TN 38018
6472 Patmore Rd, Memphis, TN 38134
3890 Highway 25 70 E, Del Rio, TN 37727
1911 Hickory Valley Rd, Chattanooga, TN 37421
356 Anderson St, Limestone, TN 37681
Professional information
Senior Research Scientist I, Medicinal Chemistry &Amp; Intellectual Property At Gtx, Inc.
Position:
Senior Research Scientist I, Medicinal Chemistry & Intellectual Property at GTx, Inc., Adjunct Professor at University of Tennessee Health Science Center
Location:
Greater Memphis Area
Industry:
Pharmaceuticals
Work:
GTx, Inc.
- 3 North Dunlap St., Memphis, TN 38163 since Dec 2011
-
Senior Research Scientist I, Medicinal Chemistry & Intellectual Property
University of Tennessee Health Science Center
- Greater Memphis Area since Jun 2011
-
Adjunct Professor
American Chemical Society
- Memphis Local Section of the American Chemical Society Jan 2011 - Dec 2011
-
Chair
GTx, Inc.
Jun 2004 - Dec 2011
-
Research Scientist and Legal Liaison
Education:
University of Tennessee-Health Science Center 2002 - 2005
Doctor of Philosophy (Ph.D.), Pharmaceutical Sciences (Medicinical Chemistry Division) University of Tennessee-Health Science Center 1998 - 2002
Doctor of Pharmacy (Pharm.D.), Pharmacy University of Tennessee-Knoxville 1995 - 1998
Master of Science (M.S.), Biochemistry and Molecular Biology University of Tennessee at Martin 1989 - 1994
Bachelor of Science (B.S.), Chemistry and Biology
Doctor of Philosophy (Ph.D.), Pharmaceutical Sciences (Medicinical Chemistry Division) University of Tennessee-Health Science Center 1998 - 2002
Doctor of Pharmacy (Pharm.D.), Pharmacy University of Tennessee-Knoxville 1995 - 1998
Master of Science (M.S.), Biochemistry and Molecular Biology University of Tennessee at Martin 1989 - 1994
Bachelor of Science (B.S.), Chemistry and Biology
Research Scientist And Legal Liaison At Gtx, Inc.
Position:
Research Scientist and Legal Liaison at GTx, Inc.
Location:
Greater Memphis Area
Industry:
Pharmaceuticals
Work:
GTx, Inc.
-
Research Scientist and Legal Liaison
Education:
University of Tennessee-Health Science Center 1998 - 2005
Michael Mohler - Memphis, TN
Work:
GTx, Inc.
Senior Research Scientist I, Medicinal Chemistry & Intellectual Property
Senior Research Scientist I, Medicinal Chemistry & Intellectual Property
Selective Androgen Receptor Modulators, Analogs And Derivatives Thereof And Uses Thereof
US Patent:
2009015, Jun 18, 2009
Filed:
Jul 19, 2007
Appl. No.:
11/826985
Inventors:
James T. Dalton - Upper Arlington OH, US
Duane D. Miller - Germantown TN, US
Igor Rakov - Marion AR, US
Casey Bohl - Columbus OH, US
Michael L. Mohler - Memphis TN, US
Duane D. Miller - Germantown TN, US
Igor Rakov - Marion AR, US
Casey Bohl - Columbus OH, US
Michael L. Mohler - Memphis TN, US
International Classification:
A61K 31/495, C07C 311/10, A61K 31/18, C07C 215/68, A61K 31/135, C07D 307/02, A61K 31/34, C07D 207/12, A61K 31/4015, C07D 305/12, C07C 255/49, A61K 31/275, C07D 213/57, A61K 31/435, C07D 241/04, A61P 15/16, A61P 35/00, A61P 5/00, A61P 19/08, A61P 21/00, A61P 3/10
US Classification:
51425503, 564 89, 514604, 564443, 514646, 549478, 514473, 548544, 514425, 549313, 558423, 514525, 546330, 514277, 544383
Abstract:
This invention provides new compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, prostate cancer, muscle wasting diseases and/or disorders or a bone-related diseases and/or disorders.
Nuclear Receptor Binding Agents
US Patent:
2009006, Mar 5, 2009
Filed:
Nov 28, 2006
Appl. No.:
11/604884
Inventors:
James T. Dalton - Upper Arlington OH, US
Christina Barrett - Oakland TN, US
Yali He - Germantown TN, US
Seoung-Soo Hong - Collierville TN, US
Duane D. Miller - Germantown TN, US
Michael L. Mohler - Memphis TN, US
Ramesh Narayanan - Cordova TN, US
Zhongzhi Wu - Memphis TN, US
Christina Barrett - Oakland TN, US
Yali He - Germantown TN, US
Seoung-Soo Hong - Collierville TN, US
Duane D. Miller - Germantown TN, US
Michael L. Mohler - Memphis TN, US
Ramesh Narayanan - Cordova TN, US
Zhongzhi Wu - Memphis TN, US
International Classification:
A61K 31/4545, C07C 233/64, A61K 31/166, A61K 31/445, C07D 401/02, C07K 14/72, C07D 211/60, C07D 213/81, A61K 31/44
US Classification:
514318, 564176, 514622, 514317, 546215, 546323, 514354, 546194, 530409
Abstract:
The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
Nuclear Receptor Binding Agents
US Patent:
2009003, Jan 29, 2009
Filed:
Jan 22, 2008
Appl. No.:
12/010225
Inventors:
James T. Dalton - Arlington OH, US
Duane D. Miller - Germantown TN, US
Michael L. Mohler - Memphis TN, US
Seoung-Soo Hong - Collierville TN, US
Zhongzhi Wu - Memphis TN, US
Devesh Srivastava - Collierville TN, US
Duane D. Miller - Germantown TN, US
Michael L. Mohler - Memphis TN, US
Seoung-Soo Hong - Collierville TN, US
Zhongzhi Wu - Memphis TN, US
Devesh Srivastava - Collierville TN, US
International Classification:
A61K 31/47, C07D 217/00, A61P 25/00, A61P 9/00
US Classification:
514307, 546149
Abstract:
The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBAs are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, inflammatory diseases, oxidative stress related disorders such as Parkinson's and stroke, neurological disorders, ophthalamic disorders, cardiovascular disease, and obesity.
Nuclear Receptor Binding Agents
US Patent:
8637706, Jan 28, 2014
Filed:
Jan 31, 2012
Appl. No.:
13/362242
Inventors:
James T. Dalton - Lakeland TN, US
Christina Barrett - Oakland TN, US
Duane D. Miller - Germantown TN, US
Seoung-Soo Hong - Collierville TN, US
Yali He - Germantown TN, US
Michael L. Mohler - Memphis TN, US
Ramesh Narayanan - Cordova TN, US
Zhongzhi Wu - Collierville TN, US
Christina Barrett - Oakland TN, US
Duane D. Miller - Germantown TN, US
Seoung-Soo Hong - Collierville TN, US
Yali He - Germantown TN, US
Michael L. Mohler - Memphis TN, US
Ramesh Narayanan - Cordova TN, US
Zhongzhi Wu - Collierville TN, US
Assignee:
Gtx, Inc. - Memphis TN
International Classification:
C07C 233/65, A61K 31/165
US Classification:
564179, 564171, 514617, 514619
Abstract:
The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
Nuclear Receptor Binding Agents
US Patent:
8158828, Apr 17, 2012
Filed:
Apr 16, 2007
Appl. No.:
11/785251
Inventors:
James T. Dalton - Upper Arlington OH, US
Christina Barrett - Oakland TN, US
Yali He - Germantown TN, US
Seoung-Soo Hong - Collierville TN, US
Duane D. Miller - Germantown TN, US
Michael L. Mohler - Memphis TN, US
Ramesh Narayanan - Cordova TN, US
Zhongzhi Wu - Memphis TN, US
Christina Barrett - Oakland TN, US
Yali He - Germantown TN, US
Seoung-Soo Hong - Collierville TN, US
Duane D. Miller - Germantown TN, US
Michael L. Mohler - Memphis TN, US
Ramesh Narayanan - Cordova TN, US
Zhongzhi Wu - Memphis TN, US
Assignee:
GTx, Inc. - Memphis TN
International Classification:
C07C 233/65, A61K 31/165
US Classification:
564179, 564170, 564176, 564177, 514617
Abstract:
The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
Selective Androgen Receptor Modulators, Analogs And Derivatives Thereof And Uses Thereof
US Patent:
8110562, Feb 7, 2012
Filed:
Jul 19, 2007
Appl. No.:
11/826987
Inventors:
James T. Dalton - Upper Arlington OH, US
Duane D. Miller - Germantown TN, US
Igor Rakov - Marion AR, US
Casey Bohl - Columbus OH, US
Michael L. Mohler - Memphis TN, US
Duane D. Miller - Germantown TN, US
Igor Rakov - Marion AR, US
Casey Bohl - Columbus OH, US
Michael L. Mohler - Memphis TN, US
Assignee:
University of Tennessee Research Foundation - Knoxville TN
The Ohio State University Research Foundation - Columbus OH
The Ohio State University Research Foundation - Columbus OH
International Classification:
A61K 31/473, A61K 31/675, C07D 219/04, C07D 215/06
US Classification:
514 80, 514297, 514311, 546102, 546104, 546107, 546165, 546166
Abstract:
This invention provides nuclear hormone receptor binding compounds, compositions comprising the same and methods of uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, prostate cancer and/or diseases or disorders of bone and muscle.
Aldo-Keto Reductase Subfamily 1C3 (Akr1C3) Inhibitors
US Patent:
2013011, May 9, 2013
Filed:
Sep 7, 2012
Appl. No.:
13/607633
Inventors:
James T. DALTON - Lakeland TN, US
Duane D. Miller - Germantown TN, US
Ramesh Narayanan - Cordova TN, US
Muralimohan Yepuru - Bartlett TN, US
Christopher C. Coss - Bartlett TN, US
Michael L. Mohler - Memphis TN, US
Zhongzhi Wu - Collierville TN, US
Duane D. Miller - Germantown TN, US
Ramesh Narayanan - Cordova TN, US
Muralimohan Yepuru - Bartlett TN, US
Christopher C. Coss - Bartlett TN, US
Michael L. Mohler - Memphis TN, US
Zhongzhi Wu - Collierville TN, US
International Classification:
C07D 217/24
US Classification:
514309, 546141
Abstract:
The present invention relates to a novel class of AKR1C3 inhibitors, to compositions containing them, to methods for their preparation, and to methods of use thereof. The AKR1C3 inhibitors may be useful in the treatment of, for example, prostate cancer, benign prostate hyperplasia (BPH), lung cancer, acne, seborrhea, hirsuitism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, uterine cancer, uterine fibroids, endometriosis, myeloma and leiomyoma.